Page 1 of 3



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application

Jorgen Carlsson, et al.

Serial No.

10/563,310

Filed

May 10, 2006

For

POLYPEPTIDES HAVING BINDING AFFINITY FOR

HER2

Examiner

Attorney Docket

102821-202

Group Art Unit

Confirmation No.

6946

Customer No.

27267

Bv

Elizabeth A Galletta Registration No. 52,941 Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

[X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- [] 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. \$1.97(e)(1); and no fee is required under 37 C.F.R. \$1.17(p).
 - [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
 - Please charge Deposit Account No. <u>23-1665</u> in the amount of \$180.00 in payment of the fee under 37 C.F.R. \$1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
 - [] A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(p).
- [] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
 - a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- Please charge Deposit Account No. <u>23-1665</u> in the amount of \$130.00 in payment of the fee under 37 C.F.R. \$1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. \$1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

Jorgen Carlsson, et al.

Date: ///17/2006

Elizabeth A. Galletta

Registration No. 52,941 Attorney for Applicant

WIGGIN AND DANA LLP

One Century Tower

New Haven, CT 06508-1832 Telephone: (203) 498-4400 Telecopier: (203) 782-2889

\17451\8\623370.1

FORM I	PTO-1449	05				
INFORMATION DISCLOSORE STATEMENT BY APPLICANT			ATTY. DOCKET NO. 102821-202		SERIAL NO. 10/563,310	
	(NC	2 0 2006 E	APPLICANT: Jorgen (Carlsson, et al.		
			FILING DATE: 10 May 2006		GROUP:	
		TRABANA	U.S. PATENT DOCUMENTS			
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPR.
			· · · · · · · · · · · · · · · · · · ·			
		FC	DREIGN PATENT DOCUMENT	 S		
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION Yes No
<u> </u>			JDING AUTHOR, TITLE, DATE			-
	human IgG ₁ ," 61.	23 Protein Eng	al analysis of the interac gineering, Vol. 6, No. 4	., 1993, pag	es 441-448.	
	Nord, K., et al., " Engineering, Vol	A combinator . 8, No. 6, 199	ial library of an α-helica 95, pages 601-608.	al bacterial re	eceptor domain	," Protein
EXAMINER:				ATE CONSIDER	en.	
	DATE CONSIDERED: nitial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not					